<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315364</url>
  </required_header>
  <id_info>
    <org_study_id>107CS-5</org_study_id>
    <nct_id>NCT03315364</nct_id>
  </id_info>
  <brief_title>Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daehwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daehwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and
      Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II clinical trial
Multicenter, Open-label, Single arm, Simon's optimal two-stage design
Phase III clinical trial
Multicenter, Prospective Randomized Open-label Blinded Endpoint (PROBE) design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[Phase II] Objective Response Rate (ORR)</measure>
    <time_frame>Participants will be followed every 6 weeks until progression, an expected average of 9 months.</time_frame>
    <description>Objective Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Phase III] Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization, assessed up to 18 months.</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[Phase II] Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization, assessed up to 18 months.</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase III] Objective Response Rate (ORR)</measure>
    <time_frame>Participants will be followed every 6 weeks until progression, an expected average of 9 months.</time_frame>
    <description>Objective Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Overall Survival(OS)</measure>
    <time_frame>Until 6 months after the last participant is enrolled, assessed minimum to 18 months.</time_frame>
    <description>Overall survival(OS) is defined as the time from the date of inclusion to the date of death, regardless of the cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Time to Treatment Failure(TTF)</measure>
    <time_frame>through study completion, an expected average of 4.5 year.</time_frame>
    <description>TTF is defined as the time from the randomization date to the date of discontinuation of treatment, regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Disease Control Rate(DCR)</measure>
    <time_frame>through study completion, an expected average of 4.5 year.</time_frame>
    <description>DCR is defined as the percentage of subjects who were evaluated for complete response(CR), partial response(PR), and stable disease(SD) as the best response among from randomization to End of treatment(EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Quality of life(QoL)</measure>
    <time_frame>C1D1, C2D1, C4D1, C7D1, C10D1 (each cycle is 28 days) and study completion, up to 18 months.</time_frame>
    <description>To evaluate changes versus baseline using the EQ-5D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>Up to 28 days after last investigational product administraion.</time_frame>
    <description>Number and Description of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Recurrent or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Liporaxel® (oral paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.
Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxol® (IV paclitaxel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.
Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral paclitaxel</intervention_name>
    <description>Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent</description>
    <arm_group_label>Liporaxel® (oral paclitaxel)</arm_group_label>
    <other_name>Liporaxel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel injection</intervention_name>
    <description>Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent</description>
    <arm_group_label>Taxol® (IV paclitaxel)</arm_group_label>
    <other_name>Taxol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion/exclusion criteria

          -  Histologically or cytologically confirmed to have recurrent, or metastatic breast
             cancer.

          -  Measurable disease (revised RECIST, version 1.1).

          -  Hormone receptor (ER/PR) positive or negative, HER2 negative.

          -  Subjects were eligible for the study regardless of their previous lines of endocrine
             therapy.

          -  No prior chemotherapy is allowed in metastatic disease.

          -  Subjects who administrated the last dose of taxane class drug ≥12months ago as from
             the first administration day.

          -  ECOG performance status ≤1.

          -  Neuropathy grade &lt;2.

          -  Subjects with central nervous system metastasis should be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-bae Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-bae Kim, M.D., Ph.D</last_name>
    <phone>82-2-3010-3217</phone>
    <email>sbkim3@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy Of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Binghe Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shusen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Hainan Medical College</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinsheng Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongsheng Tong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jifeng Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongmei Yin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shangdong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huihui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingfen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xichuan Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong university</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China School Of Medicine Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Luo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia Wang Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang University School Of Medicine Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xian Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Hyeong Lee, M.D.</last_name>
      <phone>82-43-269-6015</phone>
      <email>kihlee@chungbuk.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <state>Gangwon-do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung Taek Lim, M.D.</last_name>
      <phone>82-10-3470-6566</phone>
      <email>darksgtlim@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun Seok Lee, M.D., Ph.D</last_name>
      <phone>82-31-920-1623</phone>
      <email>kslee@ncc.re.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cha University Cha Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Wha Moon, Ph.D.</last_name>
      <phone>82-10-2825-6357</phone>
      <email>ymoon@cha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Yun Kang, M.D.,Ph.D</last_name>
      <phone>82-31-219-4911</phone>
      <email>kagnsy01@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>612-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myoung-joo Kang, M.D.</last_name>
      <phone>82-51-797-0001</phone>
      <email>daniel0602@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Mi Lee</last_name>
      <phone>82-51-990-6532</phone>
      <email>byule00@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Yeon Oh</last_name>
      <phone>82-55-360-2369</phone>
      <email>manic2db@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keon Uk Park</last_name>
      <phone>82-53-258-7716</phone>
      <email>kupark@dsmc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35365</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Gwon Choi</last_name>
      <phone>82-42-600-9434</phone>
      <email>jabuss@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gang Neung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Suk Oh</last_name>
      <phone>82-33-610-3136</phone>
      <email>hosukoh@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Kyung Ahn</last_name>
      <phone>82-10-9933-5099</phone>
      <email>hkahn.onco@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-hwa Park, M.D., Ph.D</last_name>
      <phone>82-2-920-6841</phone>
      <email>khpark@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-yong Kim, M.D., Ph.D</last_name>
      <phone>82-2-765-6433</phone>
      <email>ktyongmd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Hyuk Sohn, M.D.,Ph.D</last_name>
      <phone>82-2-2228-8135</phone>
      <email>oncosohn@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-bae Kim, M.D., Ph.D</last_name>
      <phone>82-2-3010-3217</phone>
      <email>sbkim3@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hyuck Im, M.D., Ph.D</last_name>
      <phone>82-2-3410-3445</phone>
      <email>yh00.im@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hong Seo, M.D., Ph.D</last_name>
      <phone>82-2-2626-3059</phone>
      <email>cancer@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Eun Lee</last_name>
      <phone>82-10-8934-9310</phone>
      <email>befamiliar@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jee Hung Kim</last_name>
      <phone>82-2-2019-3310</phone>
      <email>OK8504@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uijeongbu ST. Mary's Hospital</name>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Der Sheng Sun</last_name>
      <phone>82-10-2717-9652</phone>
      <email>ds-sun@daum.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>MBC</keyword>
  <keyword>Firstline chemotherapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Liporaxel</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

